Click here to view the July edition of eNews.
Newcells Biotech, a pioneering life-sciences spin-out that applies Human induced Pluripotent Stem Cells (hiPSCs) to develop assays for drug development, have consolidated their two laboratory sites into 500m2 of laboratory and co-located office space in The Biosphere, which forms part of the Newcastle Helix cluster.
Cambridge, UK, 22nd June 2020: TTP plc (TTP), a leading independent technology and product development company, today announced that it has entered into a technology advisory partnership with Cancer Research UK. TTP has been selected by Cancer Research UK to apply its technology design and development expertise and insight in the healthcare sector, to assess discoveries made by the charity’s academic researchers.
AMSBIO has launched a range of ready-to-use SARS-CoV-2 Spike protein coupled magnetic beads that combine convenience, minimum non-specific binding and developed operational protocols saving you time and hassle.
The AMR Centre has combined forces to attract much needed investment to combat the global threat of antimicrobial resistance (AMR) resulting in a successful bid for a £114 million project supported by UK Research and Innovation (UKRI). The funding was secured by a North West UK based consortium that will work in partnership to create an integrated platform for the development of new treatments and diagnostics for infectious diseases.
As part of the agreement, Biocair will transport selected blood samples to specialist laboratories for investigation to find out if the individual has developed antibodies against the SARS-CoV-2 virus.
The Bundesliga was the first European football league to restart amidst the ongoing pandemic. As a result, the league has implemented several protective measures to guard staff and players against COVID-19. This includes mandatory testing across all clubs.
Miguel Rodriguez, Client Relationship Manager at Biocair GmbH, comments:
25 June 2020, Oxfordshire, UK
Scientists from UK-headquartered AI precision medicine company, PrecisionLife, have found 68 genes associated with risk of developing severe COVID-19 by using its proprietary AI-enabled precision medicine platform to analyze the genomes of 929 patients from the UK Biobank who had a severe response to SARS-CoV-2.
- Start Codon aims to rapidly translate the most disruptive and innovative life science research into successful companies and positive clinical outcomes
- The first cohort of four companies will debut at the Milner Therapeutics Symposium on the 26th June and at OnHelix on the 14th July